Ever wondered how new and experimental Parkinson’s medicines make it to market? Dr Kieran Breen – of the European Medicines Agency Committee for Advanced Therapies – gives us the lowdown on the rigorous approval process
All advanced therapy medicinal products (ATMPs) are regulated in Europe by the Committee for Advanced Therapies of the European Medicines Agency (EMA CAT).
This specialised group was established in 2009 and contains experts from all of the EU member states in addition to two representatives nominated by patient organisations and healthcare professional bodies.
I was nominated by the European Parkinson’s Disease Association (Parkinson’s Europe) as one of the patient organisation representatives on the CAT.